Blocker Array from BACHEM

Products	Blocker Array from BACHEM
Company	BACHEM
Item	Blocker Array
Price	$35.00
Description	Blocker Arrays can be used to test the crossreactivity of an antibody against various proteins and sera that are commonly used as blocking reagents or antigen carriers. The array contains spots for 21 different protein preparations on a nitrocellulose membrane. Application: Determination of antibody crossreactivity and species specificity, QC of purified antibodies, selection of suitable blockers for Western blot, ELISA and IHC, identification of an unknown carrier in an immunogenic conjugate, clarification of high background and/or unexpected binding. Storage: 2-8 C
Info	BACHEM Peninsula Laboratories Inc. A Member of the Bachem Group 305 Old County Road San Carlos, California 94070 Customer Service: 650-592-5392 800-922-1516 Fax Number: 650-595-4071 Web Site: http://www.bachem.com/

NOTE: Price information is approximate list price and actual prices may vary.

TAG: Blocker Array from BACHEM

EDG-1 Western blot control from Exalpha Biologicals, Inc.

Stem Cell Expansion Media 1 from 3H Biomedical AB

Human TIMP-1 ELISpot Development Kit from R&D Systems

BD IMagnet 1 each from BD Biosciences Pharmingen

Biology Products:

EDG-1 Western blot control from Exalpha Biologicals, Inc.Stem Cell Expansion Media 1 from 3H Biomedical AB Human TIMP-1 ELISpot Development Kit from R&D Systems BD IMagnet 1 each from BD Biosciences Pharmingen

(Date:11/30/2009)...al for infection. Each binds a specific receptor o... host cell to take up the pathogen. Normally, thes...or example the regulation of cell growth and wound...hed in the current issue of the " Journal of Molec...rces for Listeria infections leading to listerio...

(Date:11/30/2009)...irus,s exquisite specialisation for its human host... the humble lab mouse, can deliver only limited in...ioMed Central,s open access Journal of Biology h...reating a mouse that has key features of HIV infec...assiotis, from the Division of Immunoregulation at...

(Date:11/30/2009)... 30 Neurotechnology ( http://www.n... biometric identification technologies, has releas...line: VeriLook 4.0 Software Development Kit (SDK... for large-scale multi-biometric and automated fin...apabilities in VeriLook 4.0 provide enhanced facia...

Breaking Biology News(10 mins):It takes 2 to infect 2 A reductionist approach to HIV research 2 New VeriLook 4.0 for Biometric Facial Recognition and MegaMatcher 3.1 for Multi-biometric Applications Are Now Available 2 New VeriLook 4.0 for Biometric Facial Recognition and MegaMatcher 3.1 for Multi-biometric Applications Are Now Available 3 New Vision Device Passes Virtual Collision Test for People with Tunnel Vision 13741 1 New Vision Device Passes Virtual Collision Test for People with Tunnel Vision 13741 2 New Vision Device Passes Virtual Collision Test for People with Tunnel Vision 13741 3 New treatment in sight for ovarian cancer 55732 1 New treatment in sight for ovarian cancer 55732 2 Women blacks Medicare recipients less likely to be evaluated for liver transplantation 55728 1 Women blacks Medicare recipients less likely to be evaluated for liver transplantation 55728 2

[0] It takes 2 to infect [0] A reductionist approach to HIV research [0] New VeriLook 4.0 for Biometric Facial Recognition and MegaMatcher 3.1 for Multi-biometric Applications Are Now Available

...team of scientists offer a compendium of air pollu...pacts on humans and the environment, while address...uses of fire as a land management tool. , The 686...85 experts from various science disciplines who st...rope, Asia, and Australia from prehistoric times t...

...y of Plant Biologists members Professor David Salt...sity) along with Jeremy Friedberg (Spongelab) have... category of the Science magazine 2008 Science a...ng project is an interactive biology gaming module...ence and Engineering Visualization Challenge is a ...

... cap has been a focal point of recent climate chan...ediate global warming than the larger Antarctic ic...has been melting, it is still not clear how much t... further research is needed. A framework for such ...d by the European Science Foundation (ESF). , "T...

Other Biology News:Book explores global implications of wildland fire smoke 2 David Salt is 'worth his salt,' says Science magazine 2 David Salt is 'worth his salt,' says Science magazine 3 What is really happening to the Greenland icecap? 2

Book explores global implications of wildland fire smoke David Salt is 'worth his salt,' says Science magazine What is really happening to the Greenland icecap?

(Date:11/30/2009)...TERDAM, November 30 Biopharmaceuti... first patients have been enrolled in its,multinat...he study is,designed to show reduction in transpla...g an allogeneic stem cell transplantation with a m...patients eligible for an allogeneic,stem cell tran...

(Date:11/30/2009)...LE, Md., Nov. 30 Novavax...pleted enrollment in the Phase II clinical study o...mmended strains) VLP vaccine candidate in healthy ...his randomized, double-blind, active-controlled st...nogenicity of two different doses (15 mcg and 60 m...

(Date:11/30/2009)...ATTLE, Nov. 30 Cell Ther...ced today that its new class of platinum-based ant...ated a stronger anti-tumor potency and activity co...unds as well as the ability to overcome cisplatin-... presented in a paper titled "Novel Bis-platinum C...

(Date:11/30/2009)... LONDON, November 30 ApaTech, ...med Europe,s fastest growing,Biotech/Pharmaceutica...itte,2009 Technology Fast 500 for EMEA (Europe, Mi...ing is based on a companies, five-year revenue gro...8% over this period. This,achievement places ApaTe...

Breaking Biology Technology:Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM) 2 NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 2 NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 3 NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 4 New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 2 New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 3 ApaTech is Europe's Fastest Growing Lifescience Company 2 ApaTech is Europe's Fastest Growing Lifescience Company 3 ApaTech is Europe's Fastest Growing Lifescience Company 4

[0] Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM)[0] NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults [0] New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents [0] ApaTech is Europe's Fastest Growing Lifescience Company